TABLE 3.
Descriptives of bc-ΔHRSD response profiles: mean (SD) or count (column%)
| Variable | Early Remission |
Delayed remission |
Gradual remission |
Minimal response |
No response |
All subjects | Za | P |
|---|---|---|---|---|---|---|---|---|
| HRSD baseline | 20.6 (3.6) | 21.6(4.3) | 19.2 (3.5) | 19.9 (4.0) | 18.4 (3.0) | 19.8 (3.8) | −1.82 | 0.068 |
| HRSAb baseline | 16.1 (5.3) | 16.7 (4.6) | 15.8 (5.4) | 16.2 (5.3) | 15.6 (4.6) | 16.1 (5.2) | −0.11 | 0.909 |
| Age of onset MDD | 30.0 (13.3) | 28.9 (13.8) | 30.1 (13.0) | 31.2 (15.0) | 33.3 (16.3) | 30.7 (14.2) | 1.2 | 0.229 |
| CTQc total | 47.4 (16.2) | 44.3 (14.4) | 44.8 (16.4) | 46.3 (15.2) | 44.0 (13.5) | 45.6 (15.5) | −0.14 | 0.888 |
| Male | 20 (46.5%) | 12 (50.0%) | 47 (42.3%) | 58 (42.0%) | 11 (39.3%) | 148 (43.0%) | −0.76 | 0.45 |
| Race | ||||||||
| Non-Hispanic White | 15 (38.5%) | 11 (50.0%) | 51 (47.7%) | 64 (51.2%) | 15 (57.7%) | 156 (48.9%) | – | – |
| Non-Hispanic Black | 7 (17.9%) | 3 (13.6%) | 17 (15.9%) | 28 (22.4%) | 6 (23.1%) | 61 (19.1%) | 0.46 | 0.649 |
| Hispanic | 17 (43.6%) | 8 (36.4%) | 39 (36.4%) | 33 (26.4%) | 15 (19.2%) | 102 (32.0%) | −2.35 | 0.019 |
| Previous episodes | ||||||||
| 1 | 21 (50.5%) | 13 (54.2%) | 65 (59.1%) | 60 (44.4%) | 18 (64.3%) | 177 (52.2%) | – | – |
| 2 | 9 (21.4%) | 5 (20.8%) | 16 (14.5%) | 32 (23.7%) | 1 (3.6%) | 63 (18.6%) | 0.03 | 0.974 |
| 3+ | 12 (28.6%) | 6 (25.0%) | 29 (26.4%) | 43 (31.9%) | 9 (32.1%) | 99 (29.2%) | 0.87 | 0.384 |
| Current anxiety disorder | 12 (27.9%) | 8 (33.3%) | 50 (45.0%) | 59 (42.8%) | 10 (35.7%) | 139 (40.4%) | 0.91 | 0.361 |
| Melancholic subtype | 23 (53.5%) | 15 (62.5%) | 62 (55.9%) | 77 (55.8%) | 16 (57.1%) | 193 (56.1%) | 0.02 | 0.984 |
| Chronic (current episode ≥ 2 years) | 15 (35.7%) | 5 (21.7%) | 30 (27.3%) | 46 (34.3%) | 10 (35.7%) | 106 (31.5%) | 0.88 | 0.381 |
| Full time employment | 24 (57.1%) | 14 (58.3%) | 40 (36.0%) | 68 (49.6%) | 11 (39.3%) | 157 (45.9%) | −0.49 | 0.621 |
| Family hx mood disorder | 17 (39.5%) | 10 (41.7%) | 45 (40.5%) | 60 (43.5%) | 7 (25.0%) | 139 (40.4%) | −0.41 | 0.684 |
| Treatment group | ||||||||
| Escitalopram | 21 (48.8%) | 5 (20.8%) | 34 (30.6%) | 49 (35.5%) | 5 (17.9%) | 114 (33.1%) | – | – |
| CBT | 7 (16.3%) | 8 (33.3%) | 39 (35.1%) | 46 (33.3%) | 15 (53.6%) | 115 (33.4%) | 2.00 | 0.045 |
| Duloxetine | 15 (34.9%) | 11 (45.8%) | 38 (34.2%) | 43 (31.2%) | 8 (28.6%) | 115 (33.4%) | 0.03 | 0.972 |
a
Tests of significance are for prediction of response profile as an ordinal outcome measure (1–5); comparison of “all subjects” column to response category indicates the direction of the differences.
b
Hamilton Rating Scale for Anxiety.
c
Childhood Trauma Questionnaire.